Imik

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Imik

Property Description
Active ingredient Imiquimod
Form Topical Cream (Dermatological Preparation)
Pharmacological class Immune Response Modifier (Immunostimulant)
Common use Enhancing local immune defenses
Origin Synthetic Compound (Imidazoquinoline-amine)

The Core Identity: What Type of Medicine is Imiquimod?

Imik is a prescription-only medicine containing the active ingredient Imiquimod, which is precisely categorized as an Immune Response Modifier. This high-level pharmacological classification highlights its ability to influence the body's defensive systems, setting it apart from non-specific surface treatments. Imiquimod is a synthetic compound, derived from the imidazoquinoline-amine structure, meaning it is manufactured to possess specific biological activity rather than being sourced directly from natural materials. This foundational design is clinically recognized for initiating an active cellular response locally, unlike older, passive agents.


Form, Composition, and General Purpose

The medication is supplied as a topical cream, serving as a specialized dermatological preparation intended solely for external use and local application, typically by adult patients. As a single-ingredient product, its core composition features the active substance, Imiquimod, compounded into an emollient base. This formulation ensures that the therapeutic action is concentrated at the application site, which is a differentiating factor for treatments targeting small, defined areas. The general purpose of Imik is to promote a focused and protective immune response within the skin. It achieves this by activating immune cells via the Toll-like receptor 7 (TLR7) pathway, a mechanism that results in the local induction of interferons and cytokines. This process essentially instructs local immune cells to clear compromised or abnormal skin growths, providing a non-destructive method for managing certain skin conditions.

Regulatory References

  1. Imiquimod - MedlinePlus Drug Information

What side effects are possible with Imik?

Possible Side Effects and Safety Information

The safety profile of Imiquimod cream is characterized by adverse reactions officially documented and classified by regulatory authorities. As a topical Immune Response Modifier, the most frequent effects are generally localized to the site of application, though systemic reactions are also noted in official labeling.


Adverse Reaction Scope and Classification

Adverse reactions are classified according to standard regulatory frequency bands:

Classification Examples of Documented Reactions
Very Common (ge 1/10) Local skin reactions (e.g., erythema, pruritus, scabbing, pain, burning); headache; fatigue; myalgia.
Common (ge 1/100 to < 1/10) Pyrexia (fever), nausea, dizziness, arthralgia, lymphadenopathy.

Reactions are categorized by System-Organ Classes (SOCs), with the primary effects listed under Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions.

Serious Adverse Reactions and Safety Constraints

The official label documents the potential for Serious Adverse Reactions. These include the possibility of Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), though these are classified as rare events.

Regulatory documents also define specific safety constraints. The cream is not intended for use on internal surfaces (e.g., oral, ophthalmic, or intranasal areas) and should not be applied to broken skin or open wounds. Furthermore, local skin reactions are documented as more frequently observed at the start of treatment.

Population-specific safety notes indicate that safety and efficacy are not established for pediatric patients, and caution is noted for severely immunosuppressed individuals.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents categorize overdose manifestations based on the route of excessive exposure. Overuse of Imiquimod cream through excessive topical application is primarily documented to increase the incidence and severity of expected local skin reactions, including intense erythema, erosion, scabbing, and edema. Regulatory guidance mandates that if excessive cream is applied, the site should be washed immediately with mild soap and water.

More serious systemic concerns are associated with accidental oral ingestion. Symptoms following ingestion of the cream, which contains 250 mg of the active substance in a standard 5 g tube, include nausea, vomiting, fever, headache, and myalgia. The most clinically significant event reported following high single oral doses in trials was hypotension (low blood pressure).

Emergency Action Required

Immediate medical attention must be sought in all cases of accidental oral ingestion. Regulators advise contacting a Poison Control Center immediately. If the individual has collapsed, had a seizure, or is not breathing, emergency services must be contacted without delay. Treatment for overdose is strictly symptomatic and supportive, as the official labeling states that no specific antidote is known. The hypotension documented in trials resolved following fluid administration.

Therapeutic Uses of Imik

What Imik Treats: Main Uses and Benefits

Imik, which contains the active ingredient Imiquimod, is applied topically to address specific abnormal skin and mucosal growths. This cream is generally used in situations involving certain distressing symptoms and supports the patient with a non-destructive, supportive therapeutic benefit. Its application is relevant for key dermatological conditions, including Actinic Keratoses (AK) on the face and scalp, Superficial Basal Cell Carcinoma (sBCC), and External Genital and Perianal Warts.


Key Therapeutic Applications

This cream may be part of symptomatic management across conditions presenting with localized growths. This is considered relevant when supportive symptom management is appropriate. For instance, when treating precancerous Actinic Keratoses, the application is commonly used to help with managing field cancerization. For appropriate patients with sBCC, it may be part of symptomatic management when a non-surgical approach is considered relevant.

"This application contributes to improved comfort, as it is a non-destructive topical therapy, which helps improve day-to-day comfort during symptomatic periods."

The therapeutic benefit contributes to easing the overall symptom load. For viral-associated growths like warts, Imik may assist with managing the presence of these growths over time by supporting the local immune response.

Quick Fact: Relief for Localized Growths
Imik is primarily relevant for easing the symptom burden associated with rough, scaly lesions and external wart-like growths, offering symptomatic support across these dermatological domains.

Eligibility and Restrictions for Use

Who Can and Cannot Use Imik (Imiquimod)

The eligibility for Imik cream is strictly defined by regulatory authorities based on age, physiological status, and underlying patient conditions.


Populations for Whom Use is Prohibited

Category Non-Eligibility Statement
Absolute Contraindication Patients with known hypersensitivity to Imiquimod or any cream excipients must not use this product.
Skin Integrity Application is prohibited on skin that is not intact, including open wounds, cuts, or abrasions. Treatment must wait until the skin has completely healed.

Age and Special Population Restrictions

Imik is officially approved for use in adults (18+ years) for Actinic Keratoses (AK) and Superficial Basal Cell Carcinoma (sBCC). The minimum age for the treatment of External Genital Warts (EGW) is 12 years and older.

Safety and efficacy have not been established in the general pediatric population or for conditions like AK and sBCC in patients under 18. Use in immunosuppressed patients is also not established and repeat treatment is not recommended.


Pregnancy and Lactation

Use during pregnancy is restricted and should only occur if the potential benefit justifies the potential risk. Caution is advised during lactation as it is unknown whether the active ingredient is excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Imik (Imatinib) has a significant potential for interactions, primarily due to its effects on the Cytochrome P450 (CYP) enzyme system in the liver. This medicine is metabolized mainly by the CYP3A4 enzyme and is also an inhibitor of CYP3A4 and CYP2D6, affecting the levels of many other co-administered products.

Interacting Product Category Effect on Imik Levels Clinical Recommendation
Strong CYP3A4 Inducers Decreased Avoid concomitant use; consider dose increase if unavoidable.
Strong CYP3A4 Inhibitors Increased Use caution; monitor for potential adverse effects.
Warfarin (Oral Anticoagulant) Increased risk of bleeding Avoid; use low-molecular-weight or standard heparin instead.
CYP2D6 Substrates Increased levels of the substrate drug Use caution; Imik inhibits CYP2D6 metabolism.

Substances that are strong CYP3A4 inducers (such as rifampin, phenytoin, or carbamazepine) can substantially decrease Imik concentration in the body, potentially reducing its effectiveness. Conversely, strong CYP3A4 inhibitors (such as ketoconazole or grapefruit juice) can increase Imik levels, raising the risk of adverse events. Because Imik inhibits the metabolism of other drugs, the concomitant use of warfarin is not recommended due to a heightened risk of hemorrhage. Patients requiring anticoagulation should be managed with low-molecular-weight or standard heparin.

Mechanism of Action

Imik is an immune response modifier that functions as an agonist of Toll-like receptor 7 (TLR7), primarily on antigen-presenting cells such as macrophages and plasmacytoid dendritic cells.

Binding of Imik to the intracellular domain of TLR7 triggers a signal transduction cascade involving myeloid differentiation primary response protein 88 (MyD88). This intracellular pathway leads to the nuclear translocation and activation of transcription factors, notably Nuclear Factor-kappa B (NF-kappaB) and Interferon regulatory factor 7 (IRF7). The subsequent downstream cascade involves the transcriptional upregulation and robust synthesis of various pro-inflammatory cytokines, including Interferon-alpha (IFN-alpha), Tumor Necrosis Factor-alpha (TNF-alpha), and several interleukins (e.g., IL-6, IL-8). The increased local concentration of IFN-alpha and other Th1-biasing cytokines mediates the system-level physiological consequence of amplifying both innate and adaptive immune responses, shifting the immune microenvironment toward a T-helper type 1 (Th1) profile through the generation and activity of cytotoxic effector cells.

Dosage and Administration Information

How to Use Imik (Imatinib)

This section outlines the administration instructions for Imatinib (Imik).

Administration Details

Feature Instruction
Route of Administration Oral (by mouth) only.
Timing Relative to Meals Must be taken with a meal and a large glass of water.
Dosing Schedule Most doses (e.g., 400 mg, 600 mg) are administered once daily. The highest dose (800 mg) must be split into 400 mg taken in the morning and 400 mg taken in the evening.
Missed Dose Rule If a dose is missed, do not take the missed dose. The next prescribed dose should be taken at the scheduled time.

Preparation and Special Instructions

For patients who are unable to swallow the film-coated tablets, the tablets may be prepared as a liquid suspension for immediate use. The tablet(s) must be dispersed in a specified amount of still water or apple juice (e.g., 50 mL for a 100 mg tablet or 200 mL for a 400 mg tablet). The suspension must be stirred until the tablet disintegrates and then consumed immediately.

Population-Specific Guidance

Pediatric Patients: Dosing is calculated based on Body Surface Area (BSA), typically at 340 mg/m² daily, which can be administered once daily or in two divided doses.

Hepatic Impairment: Patients with severe hepatic impairment may require a dose reduction of approximately 25% from the standard initial dose.

Duration of Treatment: Treatment should generally be continued as long as the patient benefits. For adjuvant use in Gastrointestinal Stromal Tumors (GIST), a duration of 36 months is documented.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Imik (Imiquimod)


Evidence for External Genital and Perianal Warts

Research for external genital and perianal warts was studied for by examining findings from randomized controlled trials (RCTs) and systematic reviews. These studies generally measured a primary outcome related to the measurement of complete absence of lesions, which is the outcome measured as total absence of the lesions observed in the treated areas. The patient populations in these trials mainly included immunocompetent adults. While research explores short-term symptom changes related to the treated warts, long-term outcomes are not extensively characterized beyond one year in the primary controlled trials, and data for certain groups remain insufficient.

Evidence for Actinic Keratoses on Face and Scalp

The research for Actinic Keratoses (AK) on the face and scalp was evaluated in vehicle-controlled clinical trials and longer-term observational studies. Researchers examined key measures including the measurement of complete absence of lesions of individual visible lesions and the broader field measurement. The evidence contributes to understanding symptom patterns, especially concerning the evolution of the rough, scaly lesions associated with AK. Data for certain groups remain insufficient for specific, less common presentations, such as highly thickened (hyperkeratotic) AKs.


Long-Term Research and Durability of Response

Understanding the durability of the initial measured response is key for all indications. Research has explored this through extended observation periods following the initial treatment phase. For external warts, long-term outcomes are not extensively characterized. For superficial Basal Cell Carcinoma (sBCC), studies monitored patients for patterns observed in the measurement of tumor absence for up to five years. Generally, there is limited information for long-term outcomes that compare Imiquimod directly against other therapeutic options across all indications.

Key Gaps and Areas of Research Uncertainty

A primary gap is the lack of extensive, high-quality comparative evidence across all indications that directly compares the long-term outcomes of Imiquimod against established, traditional treatments. Additionally, follow-up durations were limited in many of the initial controlled trials, meaning long-term outcomes, especially regarding disease recurrence beyond the first year or two, data are still emerging. These limitations mean study results reflect the specific conditions under which they were conducted and not necessarily all real-world patient scenarios.

Frequently Asked Questions (FAQ)

Common questions about Imik (FAQ)


Q: Is Imik a type of antibiotic?

No, Imik is classified as an Immune Response Modifier. Official sources explain that it works by activating specific immune cells via the Toll-like receptor 7 (TLR7) pathway to promote a local protective response. It is defined by regulators as an Immune Response Modifier, not an antibiotic.


Q: How quickly do people usually start feeling the effects of Imik?

Studies indicate that treatment cycles have defined durations, which can range from a few weeks up to 16 weeks, depending on the condition being addressed. Local skin reactions are documented as frequent at the start of treatment, but the final measured outcome is assessed across the full course of use specified in official documentation.


Q: Is it true that Imik can cause unusual dreams?

Adverse reaction lists in regulatory documents report insomnia (difficulty sleeping) and headache as documented side effects. However, the primary controlled clinical trial data summarized in official documents do not commonly list unusual dreams as a reported side effect.


Q: Are there any serious side effects of Imik I should be aware of?

Official labeling documents the potential for Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which are classified as rare events. The official documentation also notes the possibility of systemic, flu-like symptoms such as fever and malaise.


Q: Why is Imik sometimes used in combination with other drugs?

Official information primarily addresses how other drugs can influence Imik through drug-drug interactions, which may affect its effectiveness. Regulatory documents typically do not provide the therapeutic rationale for intentional combination uses, but they do note which uses are currently unevaluated.


Q: How is Imik generally processed by the liver?

The small amount of the medicine absorbed into the bloodstream after topical application is rapidly processed (metabolized) in the liver. Official product information states this is done mainly by the Cytochrome P450 (CYP) 3A4 enzyme system.


Q: Can Imik be taken long-term?

Imik is approved for specific treatment courses that have defined durations, such as up to 16 weeks for external genital warts or 6 weeks for a type of skin cancer. Official documents indicate that treatment is continued until clearance is observed or the maximum treatment period defined in the label is reached.


Q: Can older adults use Imik?

Official labeling indicates that Imik cream is intended for use in adults. While specific safety data in patients over 65 years are noted as limited, no specific dose adjustment or limitation based on age alone is detailed in the regulatory documents.


Q: Has there been research on Imik's use in pediatric patients?

Official product information notes its use in treating external genital and perianal warts in patients 12 years of age and older. However, studies for other uses, such as molluscum contagiosum in younger children (ages 2 to 12 years), did not demonstrate effectiveness.


Q: What is the typical length of time someone stays on Imik?

The typical duration of use is determined by the condition being managed. For example, regulatory guidelines specify up to 16 weeks for actinic keratosis (AK) and external genital warts, and 6 weeks for superficial basal cell carcinoma (sBCC).


Q: Can Imik affect my ability to drive or operate machinery?

Official product information, based on clinical data, states that Imik cream has no or negligible influence on a person's ability to drive or use machinery.


Q: Does Imik cause weight gain or weight loss?

Changes in body weight are not listed among the commonly reported adverse reactions (incidence ge 1/100) documented in the controlled clinical trials summarized in regulatory sources.


Q: Is Imik available as a generic medicine?

Yes, regulatory databases confirm that the FDA has approved generic versions of Imik cream (imiquimod topical). This means that products containing the same active ingredient are available from different manufacturers.


Q: Why do some people experience changes in mood with Imik?

Adverse reaction lists in regulatory documents report psychiatric side effects, specifically insomnia and depression, as documented in clinical trials. These effects are typically reported as uncommon (affecting less than 1 in 100 people).


Q: Can Imik be used during pregnancy?

Official labels state that there are no clinical data available regarding the use of the drug in pregnant women. The medication should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, as the potential risk is currently unknown.


Q: Can Imik cause skin sensitivity to the sun?

Yes. Official product information includes a warning to avoid exposure to sunlight and sunlamps while the cream is being used. This is because Imik can increase the skin’s sensitivity to UV light (photosensitivity).


Q: What is the half-life of Imik?

Pharmacokinetic data in regulatory documents indicate that the apparent half-life of the drug following topical application is approximately 29 hours.


Q: Can Imik affect fertility in men or women?

Official product information states that no clinical data on the effect of the medication on human fertility are available. As a result, the potential risk to human fertility is currently unknown, according to official sources.


Q: Does Imik cause constipation or diarrhea?

General gastrointestinal adverse events are not uncommon for some drugs, but regulatory summaries state that constipation or diarrhea are not listed among the common (incidence ge 1%) adverse reactions reported in the controlled clinical trials.


Q: What if I take too much Imik by accident?

Systemic overdose from topical application is considered unlikely due to minimal absorption. However, persistent dermal overdosing could lead to severe local skin reactions. Following accidental ingestion, official reports have noted temporary hypotension (low blood pressure). These episodes were observed to resolve.

How should Imik be stored and disposed of?

How to Store and Dispose of Imik

Official regulatory documents detail specific conditions required to maintain the stability and effectiveness of Imik. All storage and disposal information is based strictly on government-mandated labeling.

Storage and Handling Requirement Official Instruction
Temperature Store at controlled room temperature, 20°C to 25°C (68 F to 77 F).
Prohibitions Do not freeze or store above 30°C.
Protection Keep the product in the original container, tightly closed, and protect from light and moisture.
Stability After first opening, use within 28 days.
Child Safety Keep this and all medicines out of the reach of children.

For disposal, unused or expired Imik must be discarded according to official governmental guidance for pharmaceutical waste. Do not dispose of the medicine by flushing it down a toilet or placing it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Imik found in:

A-Z Index: